Tuesday, November 7, 2017
- 9:00AM-11:00AM
-
Abstract Number: 2438
Open Label Transitioning from Originator Etanercept to Biosimilar SB4 Compared to Continuing Treatment with Originator Etanercept in a Historical Cohort in Rheumatic Diseases in Daily Practice
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars- 9:00AM-11:00AM
-
Abstract Number: 2485
Outcomes of Switching from TNF Inhibitors to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars- 9:00AM-11:00AM
-
Abstract Number: 2240
Partnering in Research: Maximizing Benefits & Minimizing Risks in Patient-Researcher Relationships
Patient Outcomes, Preferences, and Attitudes Poster III- 9:00AM-11:00AM
-
Abstract Number: 2639
Pathological Relevance of T Follicular Helper Cell and Plasmablast in Patients with Systemic Lupus Erythematosus
Systemic Lupus Erythematosus – Human Etiology and Pathogenesis Poster II- 9:00AM-11:00AM
-
Abstract Number: 2553
Patient and Physician Global Assessment Are Poorly Inter-Connected and Poorly Explained By Other Clinical Markers of Disease Activity in Individual Patients with Psoriatic Arthritis
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 2266
Patient Knowledge, Attitudes, and Beliefs Regarding Biologic Therapies in Ankylosing Spondylitis (AS): Insights from a Large-Scale Analysis of Social Media Platforms
Patient Outcomes, Preferences, and Attitudes Poster III- 9:00AM-11:00AM
-
Abstract Number: 2030
Patient Motivation in Inflammatory Arthritis: The Use of Ultrasound-Guided Patient Education to Endorse Medication Adherence and Facilitate Cost-Effective Targeted Management
Measures and Measurement of Healthcare Quality Poster II- 9:00AM-11:00AM
-
Abstract Number: 2535
Patient Outcomes from a Tertiary Center Combined Rheumatology-Dermatology Clinic
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 2268
Patient Perspectives from a Qualitative Study Predict Non-Adherence in Rheumatoid Arthritis
ARHP Patient Outcomes, Attitudes, and Preferences Poster- 9:00AM-11:00AM
-
Abstract Number: 2460
Patient-Reported Outcomes Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars- 9:00AM-11:00AM
-
Abstract Number: 2253
Patient’s Self-Monitoring of Disease Activity of Rheumatic Diseases Via Webapp – Study Design, Patient’s Perspective and Recruitment in the First 16 Months of a Swiss Multicentre, Longitudinal Study
Patient Outcomes, Preferences, and Attitudes Poster III- 9:00AM-11:00AM
-
Abstract Number: 2423
Patients with Active Rheumatoid Arthritis but Normal Levels of Acute Phase Proteins Have Altered Regulatory T Cell Function and Rapidly Progress to Biological Therapies
Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster III- 9:00AM-11:00AM
-
Abstract Number: 2084
Patients with Early Onset Gout Develop Earlier Severe Joint Involvement and Metabolic Comorbid Conditions
Metabolic and Crystal Arthropathies Poster II- 9:00AM-11:00AM
-
Abstract Number: 2633
Patients with Secondary Sjögren’s Syndrome to SLE Are Characterized By Typical Autoantibodies and a Pro-Inflammatory State